Fig. 7.

LRP mediates the GnRH-II–induced production of MMP-2 by ovarian cancer cells. OVCAR-3 (A) and CaOV-3 (B) cells were treated with 10 nm GnRH-II for up to 72 h. Total RNA from treated cells was used to prepare cDNA for RT-qPCR analysis to evaluate the effect of GnRH-II on MMP-2 mRNA levels. RT-qPCR results are expressed as mean ± sem of three independent experiments. *, P < 0.05 compared with untreated control (Ctrl). C and D, OVCAR-3 and CaOV-3 cells were treated with 100 nm GnRHR siRNA (si-GnRHR) or 100 nm control siRNA (si-Ctrl) for 24 h and then treated with 10 nm GnRH-II for 48 h. E and F, OVCAR-3 and CaOV-3 cells were treated with 75 nm LRP siRNA (si-LRP) or 75 nm control siRNA (si-Ctrl) for 24 h and then treated with 10 nm GnRH-II for 48 h. In C–F, cells were harvested and protein extracts were subjected to Western blotting with antibodies against MMP-2, GnRHR, LRP, or β-actin as a normalization control.